Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alexandra Nanzer-Kelly"'
Autor:
Grainne D'Ancona, H. Dhruve, Alexandra Nanzer-Kelly, Jaideep Dhariwal, David A. Jackson, S. Holmes
Publikováno v:
Treatment and adherence in asthma.
Introduction and ObjectiveThe COVID-19 pandemic has witnessed a reduction in asthma exacerbations in the UK. Several factors may underpin this, including reduced transmission of seasonal viruses and improved use of or adherence to inhaled corticoster
Autor:
M Fernandes, Joanne Kavanagh, Brian D. Kent, Cris Roxas, David C. Jackson, Victoria Payne, Linda K. Green, Grainne D'Ancona, Andrew P. Hearn, Jaideep Dhariwal, L Thomson, Alexandra Nanzer-Kelly
Publikováno v:
Airway pharmacology and treatment.
Introduction: Multiple biologic therapies targeting IgE, IL-4R, IL-5 and IL-5R are licensed for severe asthma. In all cases elevated blood eosinophil count is associated with improved clinical response. An elevated FeNO has also been shown to be a bi
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Autor:
Cris Roxas, Kirsten Stewart-Knight, Mariana Fernandes, Joanna Kavanagh, DJ Jackson, Leyla Osman, Grainne D'Ancona, L. Green, Brian D. Kent, Alexandra Nanzer-Kelly
Publikováno v:
Airway pharmacology and treatment.
Mepolizumab reduces maintenance oral corticosteroid (mOCS) requirement and exacerbation frequency, while improving symptom control in patients with severe eosinophilic asthma. The impact of any changes in maintenance inhaler use in patients receiving
Autor:
Mariana Fernandes, Cris Roxas, Brian D. Kent, Louise Thompson, Joanne Kavanagh, L. Green, Grainne D'Ancona, Alexandra Nanzer-Kelly, David A. Jackson
Publikováno v:
Airway pharmacology and treatment.
Introduction: Benralizumab is a monoclonal antibody against IL-5R and is licensed for the treatment of severe eosinophilic asthma (SEA). The phase 3 ZONDA study reported significant oral glucocorticoid (OCS) sparing efficacy with benralizumab. Howeve
Autor:
David C. Jackson, Cris Roxas, L. Green, Joanna Kavanagh, Mariana Fernandes, Grainne D'Ancona, Brian D. Kent, Sangita Agarwal, Alexandra Nanzer-Kelly
Publikováno v:
Airway pharmacology and treatment.
Eosinophilic granulomatosis with polyangiitis (EGPA) is an uncommon but potentially devastating disorder characterised by perivascular eosinophilic inflammation, severe asthma, peripheral eosinophilia, and sino-nasal disease, which is frequently comp
Autor:
Cris Roxas, Louise Thompson, Maria Elstad, Abdel Douiri, David A. Jackson, L. Green, Alexandra Nanzer-Kelly, Mariana Fernandes, Grainne D'Ancona, Brian D. Kent, Lydia Shackshaft
Publikováno v:
Monitoring airway disease.
Introduction: Fractional exhaled nitric oxide (FeNO) is a non-invasive measure of Type 2 airways inflammation in asthma. It most closely reflects IL-13 levels, and along with the blood eosinophil count relates to both asthma control and exacerbation